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A loss of GABA signaling is a prevailing hypothesis for the pathogenesis of schizophrenia. Preclinical 
studies indicate that blockade of the α5 sub-type of the GABA receptor (α5-GABAARs) leads to 
behavioral phenotypes associated with schizophrenia, and post-mortem evidence indicates lower 
hippocampal α5-GABAARs protein and mRNA levels in schizophrenia. However, it is unclear if α5-
GABAARs are altered in vivo or related to symptoms. We investigated α5-GABAARs availability in in 
antipsychotic-free schizophrenia patients and antipsychotic-medicated schizophrenia patients using 
[11C]Ro15-4513 PET imaging in a cross-sectional, case-control study design. Thirty-one schizophrenia 
patients (n=10 antipsychotic free) and twenty-nine matched healthy controls underwent a [11C]Ro15-
4513 PET scan and MRI. The α5 sub-type GABA-A receptor availability was indexed using [11C]Ro15-
4513 PET imaging. Dynamic PET data were analyzed using the two-tissue compartment model with an 
arterial plasma input function and total volume of distribution (VT) as the outcome measure. Symptom 
severity was assessed using the PANSS scale. There was significantly lower [11C]Ro15-4513 VT in 
the hippocampus of antipsychotic-free patients, but not in medicated patients (p= 0.64), relative to 
healthy controls (p<0.05; Effect Size=1.4). There was also a significant positive correlation between 
[11C]Ro15-4513 VT and total PANSS score in antipsychotic-free patients (r=.72; p=.044). The results 
suggest that antipsychotic-free patients with schizophrenia have lower α5-GABAARs levels in the 
hippocampus, consistent with the hypothesis that GABA hypofunction underlies the pathophysiology 










A leading hypothesis proposes that reduced gamma-aminobutyric acid (GABA) signaling in fronto-
temporal brain regions underlies the pathogenesis of schizophrenia.1,2,3 This hypothesis is supported by 
post-mortem literature showing that schizophrenia patients relative to controls show lower mRNA and 
protein levels of the synthetic enzyme GAD67,4 lower levels of the GABA membrane transporter 
(GAT1),5 and lower expression and cell density of GABAergic interneurons relative to controls.3,6 In-
vivo studies have reported a reduction in concentrations of GABA in cerebrospinal fluid (CSF) 
concentrations in first-episode psychotic patients.7 By contrast proton magnetic resonance spectroscopy 
(1H-MRS) have yielded discrepant findings, potentially due to the technical difficulties in accurately 
resolving GABA on MRS spectra and its complex relationship with synaptic GABA.8,9 GABA acts on 
two different subtypes of receptors, GABA-A and GABA-B. The GABA-A receptor is responsible for 
the majority of the physiological actions of GABA and it includes receptor subtypes made of different 
combinations of α, β, γ, δ, ε, r, π, and θ subunits, organized in a pentameric structure arranged around 
a central pore.10 
The diversity in sub-unit composition and region-specific distribution allows GABA-A receptors to 
have distinct functional and physiological roles.11 Studies using [11C]flumazenil and [123I]iomazenil to 
index GABA receptor levels have not found differences between schizophrenia patients and healthy 
controls.12,13,14,15 However, these radiotracers are not GABA subtype-selective and show similar levels 
of uptake both in neocortex and limbic regions, which means they may be unable to detect differences 
in specific GABA receptor sub-types.16,17 In contrast, the inverse GABA-A receptor agonist [11C]Ro15-
4513 is a radioligand that binds with 10 times higher affinity (~0.5nM) to the α5 subunit of the GABA 
receptor (α5-GABAARs) when compared to other subunits (~10nM).16,18,19 Although α5-GABAARs 
represents less than 5% of all GABA-A receptors,20 they are particularly concentrated in limbic 
regions.21 In the hippocampus, a key brain region implicated in the pathogenesis of schizophrenia,22 
25% of GABA-A receptors are α5-GABAARs.21 Importantly, changes in α5-GABAARs have been 
reported in schizophrenia patients, with post-mortem studies showing lower mRNA and protein levels 
of this receptor.23,24  Moreover, an α5-GABAARs positive allosteric modulator (PAM) has been shown 
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to reverse dopaminergic hyperactivation and behavioral sensitivity to psychostimulants in 
methylazoxymethanol (MAM) treated animals, a preclinical model that reproduces many phenotypes 
seen in schizophrenia.25 In contrast, the blockade of the α5-GABAARs impairs latent inhibition26 and 
reduces prepulse inhibition to startle,27 behavioral phenotypes associated with schizophrenia. Whilst 
these converging lines of evidence implicate the α5-GABAARs in schizophrenia, the only previous PET 
study using [11C]Ro15-4513 to assess α5-GABAARs availability showed no differences in binding 
potential (BP) between patients with schizophrenia and controls.28 However, this study used a brain 
reference region approach, which is associated with an under-estimation of binding potentials, and the 
potential confound of systematic differences in GABA availability in the reference region as well.29 
Therefore, it remains unclear if α5-GABAARs availability is altered in schizophrenia patients in-vivo 
when controlling for these methodological issues. 
In view of this, we sought to investigate α5-GABAARs availability in patients with schizophrenia using 
[11C]Ro15-4513 PET imaging with an arterial input function. We hypothesized that both medicated and 
antipsychotic-free schizophrenia patients would have lower GABA-A receptor availability in the 
hippocampus when compared with healthy controls, and that GABA-A receptor availability would be 
associated with symptom severity. 
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MATERIAL AND METHODS 
Participants 
The study protocol was approved by the local Research Ethics Committee and the Administration of 
Radioactive Substances Advisory Committee, United Kingdom. All participants gave written informed 
consent prior to study participation. To control for potential sex differences in α5-GABAARs 
availability30 we specifically investigated male volunteers. Since antipsychotic medication may 
influence GABA function31,32 we recruited two groups of patients, one taking antipsychotic treatment 
and the other antipsychotic free, and compared each group with matched healthy controls. Patients on 
antipsychotics were on a stable dose of antipsychotics for at least 4 weeks prior to the scan day. A total 
of 25 medicated patients with schizophrenia or schizoaffective disorder and 19 age matched healthy 
controls were recruited. A further group of 10 antipsychotic-free patients with schizophrenia or 
schizoaffective disorder and 10 age matched healthy controls were also recruited. All patients had 
capacity to give informed written consent and satisfied DSM-V diagnostic criteria for schizophrenia or 
schizoaffective disorder as determined by the Structured Clinical Interview of DSM-V-TR Axis I 
Disorders (SCID).33  
All subjects had a physical and psychiatric examination. Urinalysis was done on the day of the scan to 
exclude the use of illicit drugs. Exclusion criteria for all participants included: female sex; history of 
head trauma or injury with loss of consciousness longer than one hour; learning disabilities or lack of 
English fluency; current or lifetime history of alcohol dependence; current or lifetime history of 
substance abuse or dependence; use of any recreational substances within the last month; current use or 
within the last month of psychotropic medication (other than an antipsychotic) with possible effects on 
the GABA system (such as antiepileptic drugs, benzodiazepines and antidepressants)34 and 
contraindications to MRI or PET. Patients were excluded if treated with clozapine, diagnosed with an 
organic psychosis or had a history of neurological or psychiatric disorders other than schizophrenia, as 
assessed by the Structured Clinical Interview for DSM-V-TR Axis I Disorders (SCID).33 Exclusion 
criteria for the antipsychotic-free patients included current or recent use of antipsychotics within the 
last 4 weeks or five half-lives of the drug (whichever was longer). The antipsychotic-free status was 
confirmed by reviewing clinical notes and pharmacy records. Healthy controls were administered the 
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Psychosis Screening Questionnaire35 (PSQ) and were excluded if they reported any psychotic symptom, 
history of psychotic illness or family history of psychosis. None of the healthy controls recruited to the 
study had a positive score in any of the PSQ questions. 
Four patients recruited into the study were excluded from participation due to PET contraindications 
(N=3) and commencement of clozapine treatment (N=1). Therefore, the final analyses include 21 
patients on antipsychotic mediation (medicated group) and 19 matched healthy controls and 10 
antipsychotic free patients (antipsychotic-free group) and 10 matched healthy controls. 
 
Clinical assessment 
Antipsychotic doses were converted to chlorpromazine equivalent dose as previously described.36 
Symptoms were evaluated using the Positive and Negative Syndrome Scale (PANSS).37 Duration of 
untreated psychosis was quantified as the interval between first psychotic symptoms and first contact 




Participants were instructed to refrain from alcohol for at least 12 hours before scanning. Dynamic PET 
scans were acquired over 90 min using a Siemens ECAT EXACT HR. (CTI/Siemens, model 962; 
Knoxville, TN, USA) scanner, with 63 trans-axial image planes covering an axial field of view of 15.5 
cm. PET emission data were corrected for attenuation and scatter using a 10-min transmission scan and 
reconstructed using Fourier re-binning and 2D filtered back-projection with a 2.0mm kernel Ramp 
filter, into 23 dynamic frames (4 x 15, 4 x 60, 2 x 150, 10 x 300 and 3 x 600 seconds). The final 
reconstructed volume had voxel dimensions of 2.059 x 2.059 x 2.000mm3. 
During the PET acquisition, arterial blood data were sampled via the radial artery using a combined 
automatic-manual approach. A continuous sampling system (ABSS Allogg, Mariefred, Sweden) was 
employed to measure whole blood activity for first 15 minutes of each scan at the rate of one sample 
per second. Discrete blood samples were manually withdrawn at 2, 5, 10, 15, 20, 25, 30, 40, 50, 60, 70, 
80, 90 minutes, centrifuged and used to determine the plasma over blood activity ratio (POB). Samples 
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at 2, 5 and 10 minutes were used to calibrate the two sampling modalities. Samples taken at 2, 5, 10, 
20, 30, 50, 70 and 90 minutes were also analysed using HPLC to calculate the plasma fraction of tracer 
free of metabolites (PPf). Both POB and PPf were fitted with an extended Hill model39 while whole 
blood TACs were fitted using a multi-exponential model40 using the Multiblood software.41 For each 
scan, a time delay was fitted and applied to the input functions (both parent and whole blood TACs) to 
account for the temporal delay between blood sample measurement and the target tissue data. 
High resolution T1 weighted volumes were acquired using a 3T MR scanner (Magneton Trio Syngo 
MR B13 Siemens 3T; Siemens AG, Germany) and a magnetization prepared rapid gradient echo 
(MPRAGE) sequence (TR = 2300 ms, TE = 2.98 ms, TI = 900 ms, flip angle = 9°, field of view = 256 
mm, image matrix = 240 x 256) with a resolution of 1 mm isotropic. For the volume, 160 abutting 
straight sagittal slices were collected in an interleaved right to the left manner, resulting in whole head 
coverage. 
 
[11C]Ro15-4513 PET data processing 
Dynamic PET data were corrected for inter-frame motion and aligned with the individual’s structural 
T1 MR image by minimizing a mutual information cost function (SPM8, Wellcome Trust Center for 
Neuroimaging, http://www.fil.ion.ucl.ac.uk/spm). A neuroanatomical atlas was also co-registered to 
each subject’s image space (MIAKAT, http://www.imanova.co.uk) and applied to the dynamic PET 
data to derive regional time-activity curves (TACs). The hippocampus was selected as our a priori 
region of interest since it has been implicated in the pathogenesis of schizophrenia and has a high 
expression of α5 GABA-A receptors relative to the rest of the brain, representing approximately 25% 
of GABA-A receptors in this region.36 Moreover, the quantification of the α5 subunit using [11C]Ro15-
4513 has been shown to be particularly reliable in the hippocampus (ICC ~0.9).42 GABA-A receptor 
availability was indexed using the distribution volume (VT) of [11C]Ro15-4513. In agreement with 
previous publications,43,44 the VT was calculated using with the metabolite-free arterial plasma input 
function and the two-tissue compartmental model (2TCM) solved with a non-linear least squares 




Statistical analyses were performed with SPSS version 20 (IBM, Armonk, N.Y.) for MAC OS X. The 
data distribution of all variables were tested using Kolmogorov-Smirnov tests and Grubbs test was used 
to determine if there were outlying data. Since all data were normally distributed, parametric tests were 
used. To test our primary hypothesis that GABA-A receptor availability would be altered in patients, 
an independent samples t-test was used to investigate if there were group differences in the VT of 
[11C]Ro15-4513 in the hippocampus in 1) medicated patients relative to age-matched healthy controls 
and 2) antipsychotic-free patients relative to age-matched healthy volunteers. Independent samples t-
tests were also used to investigate group differences in socio-demographic and clinical data. There was 
an outlier in the medicated patient group with high VT values in the hippocampus (Grubbs test p<0.05) 
and these data were excluded from further analysis. To determine whether there was an effect of group 
on VT values in our exploratory analyses of other brain regions we performed a two way-ANOVA with 
VT as the dependent variable and group (patient or control) and brain region as the independent 
variables. Exploratory analyses were also used to investigate the association between [11C]Ro15-4513 
and clinical data using Pearson’s product moment correlation. All data are presented as mean±SD, and 





Demographic and Clinical Characteristics of Study Participants 
Four groups of participants were included in the study: twenty-one patients taking antipsychotic 
mediation (medicated group) and 19 matched healthy controls and 10 antipsychotic free patients 
(antipsychotic-free group) and 10 matched healthy controls. In the medicated group, 19 patients had a 
diagnosis of schizophrenia and 2 patients had a diagnosis of schizoaffective disorder. No patient had 
any co-morbid psychiatric diagnosis as assessed by the SCID. Only one patient was taking a first-
generation antipsychotic, while the remaining 20 patients were taking a second-generation 
antipsychotic drug (supplementary data, Table S1). All of the patients in the antipsychotic-free group 
had a diagnosis of schizophrenia and were antipsychotic-free for a period of at least 4 weeks or five 
half-lives of the drug (whichever was longer). 
The demographic and clinical characteristics of the subjects are presented in Table 1. There were no 
group differences in any socio-demographic variables, or injected dose, injected mass or specific 
activity in medicated and antipsychotic-free patients and their respective healthy control groups. 
 
Hippocampus α5-GABAARs availability in patients and controls 
There was significantly lower [11C]Ro15-4513 VT in the hippocampus of antipsychotic-free patients 
when compared with healthy controls (mean ± SD: 6.90 ± 0.56 vs. 7.68 ± 0.54 respectively, p= 0.006, 
Effect Size=1.4; figures 1 and 2).  
In contrast there was no significant group difference in the [11C]Ro15-4513 VT between the medicated 
patients and healthy controls (mean ± SD: 6.94 ± 0.62 vs. 7.06 ± 0.86, p= 0.64) (Fig. 3). There was also 
no significant difference in α5-GABAARs availability between the medicated and antipsychotic-free 
schizophrenia groups (p=0.54).  
 
Correlations between hippocampus α5-GABAARs availability and clinical characteristics 
We found no significant correlation between [11C]Ro15-4513 VT and the exposure to antipsychotics, as 
measured in chlorpromazine equivalents doses (r=.32; p=.22). There was also no significant correlation 
with VT and duration of illness in either the antipsychotic-free (r=.105; p=.78) or the medicated (r=-
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.02; p=.91) groups. In the antipsychotic-free patient group, there was a significant positive correlation 
between [11C]Ro15-4513 VT and severity of symptoms, as assessed by the total PANSS score (r=.72; 
p=.044) (figure 4), which was not significant in the medicated patient group (r=.22; p=.38). There was 
also no significant correlation between [11C]Ro15-4513 VT and age in either the medicated (r=-.20; 
p=.19) or the  antipsychotic-free (r=.16; p=.49) groups. 
 
Hippocampus volume 
There were no significant differences in hippocampal volumes between antipsychotic-free patients 
relative to healthy controls and between medicated patients and healthy controls (Table 1). There were 
also no significant correlations between hippocampal volumes and the [11C]Ro15-4513 VT in the 
hippocampus in either antipsychotic-free patients (r= -.035; p=.92) or medicated patients (r=1.99; 
p=.38) 
 
Other brain regions 
In antipsychotic-free patients relative to healthy controls, there was a significant main effect of group 
on VT measures across all ROIs (F (1, 144) = 5.73, p=0.01). There was also a significant main effect of 
region on VT measures across all ROIs (F (7, 144) = 179, p<0.001). However, the group x region 
interaction was not significant (F (7, 144) = 0.61, p=0.74), and there were no significant differences in 
the post-hoc pair-wise comparisons for individual regions (supplementary data, Table S2). In the 
medicated patient group, there was no significant effect of group on VT measures across all ROIs (F (1, 
304) = 0.50, p=0.47). However, there was a significant main effect of region on VT across the brain (F 
(7, 304) = 161, P<0.001) but the group x region interaction was not significant (F (7, 304) = 0.94, 
p=0.47), and there were no significant differences in the post-hoc pair-wise comparisons for individual 






Our results show that GABA-A receptor availability, measured with a tracer selective for the α5-
GABA-A receptor subunit, is significantly lower in the hippocampi of antipsychotic-free schizophrenia 
patients, and directly correlated with symptom severity. However, α5-GABAARs availability is not 
significantly altered in antipsychotic-treated patients when compared to controls.  
Our results extend post-mortem findings showing lower mRNA and protein levels of α5-GABAARs  in 
schizophrenia patients23,24 to show evidence for lower hippocampal uptake of an α5-GABAARs selective 
tracer in vivo in untreated patients with schizophrenia. However, our results are not consistent with the 
only previous [11C]Ro15-4513 PET study in schizophrenia patients,28 where no differences in 
[11C]Ro15-4513 binding potential (BP) were observed between antipsychotic-free patients and healthy 
controls. The lack of group effects in this previous study may be due to the use of simplified reference 
tissue model (SRTM) with the pons as the reference tissue to quantify [11C]Ro15-4513 binding 
potential. This approach relies on a number of assumptions which can easily lead to biased estimates if 
violated.46 Moreover, the intra-class correlation coefficients (ICC) across brain regions range between 
0.35–0.80 when using SRTM, which indicates lower reliability than the approach we used, where ICC 
values are >0.82.42,47 The use of the pons as a reference region for [11C]Ro15-4513 PET has also been 
subject to criticism, since it may lead to the under-estimation of target binding.19,46,47 For these reasons, 
the SRTM approach used in the Asai et al. study may have lacked sensitivity to detect group differences. 
 
Interestingly, our study showed no significant differences in [11C]Ro15-4513 VT in medicated 
schizophrenia patients when compared with controls. Taken with our findings in the antipsychotic-free 
patients and other findings of lower GABA-A receptor prior to treatment,48 these results could suggest 
that there has been a normalization of α5-GABAARs levels with antipsychotic treatment. In addition, 
reduced GABA release, as assessed using a tiagabine challenge, was seen in antipsychotic-naive 
individuals but not in antipsychotic treated patients.15 Previous literature has also shown evidence of 
altered GABA levels using 1H-MRS in un-medicated patients but not in medicated patients.32 
Moreover, 4 weeks of exposure to antipsychotic treatment has also been found to normalize GABA 
levels in patients.32 Post-mortem studies also find differences between treated and untreated patients 
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with schizophrenia, showing a positive correlation between the density of GAD and antipsychotic dose 
and higher expression levels of GAD67 and GABA-A protein subunits in antipsychotic treated patients 
relative to unmedicated patients.49 However, it is important to note that both in our study and on these 
prior studies, the antipsychotic treated group had a longer duration of illness than the untreated group. 
As such, it is not possible to disentangle duration of illness from treatment effects. However, in our 
study we found no significant associations between α5-GABAARs availability and duration of illness, 
indicating that antipsychotic treatment could contribute to the lack of group differences in the treated 
patients. This is supported by preclinical findings showing an increased expression of GAD67 and 
increased GABA-A receptor binding in rats exposed to a range of different antipsychotics50 and for 
clinical studies showing that exposure to 4 weeks of antipsychotic treatment normalizes GABA levels 
in schizophrenia patients.32 However, longitudinal studies in patients are needed to test the hypothesis 
that there are changes in GABA-A receptor levels over time and if they are associated to exposure to 
antipsychotic medication. 
 
Strengths and limitations 
 
A strength of the study was that we included a large sample for a PET study and obtained arterial input 
functions.19 In our study we used the 2TCM model, which has been shown to have good reliability for 
[11C]Ro15-4513 quantification (ICC ranging from 0.83–0.88), and VT values derived from this model 
showing a close, linear relationship with α5-GABAARs specific binding.19 One potential limitation on 
generalizability is that we only included males, as there are sex differences in GABA-A receptor 
expression.30 Future studies are needed to test if our findings generalize to female patients as well. 
Although both groups are matched for age, there is a trend level difference in age between 
antipsychotic-free patients and healthy controls (p=0.06). Importantly, the VT values in our healthy 
control cohorts are similar to the ones reported in other studies using [11C]Ro15-4513 PET,51,52 
indicating that our findings are not driven by abnormal values in our controls. Furthermore, α5-
GABAARs show developmental reductions, and, supporting this, in healthy volunteers there is an 
inverse relationship between age and [11C]Ro15-4513 VT values. The lack of group differences in the 
chronic patients taken with the lower VT values could suggest disruption of the normal age-related 
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reductions in α5-GABAARs. The antipsychotic free period in the antipsychotic-free group was 4 weeks 
or over five half-lives (whichever was longer), and no antipsychotic taken in the medicated group has 
significant affinity for GABA-A receptors (all Ki values > 10,000),53,54,55,56 indicating that direct effects 
of antipsychotic drugs on GABA-A receptors are unlikely to explain our findings. We did not find any 
significant difference in hippocampal volume, suggesting that partial volume effects are unlikely to 
account for our group differences. Furthermore, although a reduction in hippocampus volume in 
schizophrenia is commonly reported,57 in our study there were no significant volumetric differences in 
hippocampal volume between patients and controls. This can be explained by the hippocampus being 
one of the brain areas with greater structural variability.58 Finally, [11C]Ro15-4513 is a highly selective 
α5-GABAARs PET radiotracer, with α5 representing around 60–70% of the specific binding in α5 rich 
regions,19 and its affinity for this subunit is approximately 10 to 20-fold greater than to other subtypes 
of the GABA-A receptor.16,17 However, it also demonstrates measurable in-vivo binding at the α1 to α4 
and α6 receptor subtype.16,17 Overall, although the [11C]Ro15-4513 VT reflects the net effect of the 
availability of these different GABA-A receptors, the 20-fold greater affinity of [11C]Ro15-4513 to α5-
GABAARs and the enriched expression of α5-GABAARs in the hippocampus indicates the lower 
[11C]Ro15-4513 hippocampal availability is likely to predominantly reflect lower α5-GABAAR levels. 
 
The interpretation of the findings and their implications for understanding schizophrenia 
GABAergic neurotransmission in the hippocampus plays a fundamental role in inhibiting the neuronal 
activity of pyramidal glutamatergic cells, through the activation of post-synaptic GABA receptors.59,60 
The hippocampus has a particularly high concentration of α5-GABAARs relative to other brain regions, 
constituting up to 25% of all GABA-A receptors in the hippocampus. Although other receptor subtypes 
are also present,61 α5 represents around 60–70% of the specific binding of [11C]Ro15-4513 in the 
hippocampus.19 While α1 and α2-GABAARs are located synaptically and involved in the phasic 
inhibition of pyramidal cells, α5-GABAARs are located mainly at extra-synaptic sites72,63  At these sites, 
α5-GABAARs are predominantly involved in generating a tonic inhibitory current64,65,66 to regulate the 
excitability of pyramidal neurons67,68 and decrease network excitability. Interestingly, this tonic 
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inhibition has shown to be at least equally important in the regulation of pyramidal cells firing as phasic 
inhibition.64 α5-GABAARs deficient mice show reduced tonic inhibition resulting in hippocampus 
hyperexcitability, which can be reversed by pharmacologically increasing the tonic current.68 The lower 
α5-GABAA receptor levels we observe may therefore be contribute to reductions in tonic inhibition, 
leading to an increase in hippocampal hyperexcitability. This interpretation is supported by previous 
literature implicating the hippocampus in the pathophysiology of schizophrenia including changes in 
hippocampal volume69 as well as changes in regional cerebral blood flow70 and blood oxygen level-
dependent (BOLD) signal.71 Taken together these suggest that lower α5-GABAARs levels could lead to 
a state of excessive excitation.60,72 Our findings are therefore consistent with hypotheses that a reduction 
in GABAergic neurotransmission disinhibits glutamatergic pyramidal neurons, resulting in the loss of 
synchronous cortical activity, and subcortical dopamine dysregulation. Furthermore, the activation of 
α5-GABAARs by positive allosteric modulator (PAM) have shown to reverse the dopaminergic and 
behavioral abnormalities observed in the MAM model.25,26,27 These findings highlight the therapeutic 
potential of targeting GABA function in schizophrenia.1,60,109 We found a significant positive correlation 
between α5-GABAARs availability and symptom severity in antipsychotic-free patients. Whilst this 
supports a link between α5-GABAARs dysregulation and the clinical expression of the disorder, the 
direction of the association is not consistent with a simple model of α5-GABAARs hypofunction leading 
to hippocampal over-activity and symptoms. It was recently shown, using a viral-mediated gene 
transfer, that an increase in the expression of α5-GABAARs normalizes VTA dopamine cell population 
activity.74 Thus, one explanation that could account for both the lower RO-15 binding in patients and a 
positive correlation with symptoms, is that low α5-GABAAR levels are a vulnerability factor but that 
once the disorder develops there is a compensatory increase in α5-GABAAR levels in response to 
dysregulation of other systems. This is consistent with the role of α5-GABAARs in providing tonic 
regulation of pyramidal neurons.75 A longitudinal study is needed to test this model further.  Finally, 
our exploratory analysis in other brain regions also showed a significant difference between 
antipsychotic-free patients and controls in the omnibus test, suggesting there may be GABA-A receptor 
alterations in other brain regions in schizophrenia. However, no individual region was significantly 
different in the pair-wise comparisons, which could reflect the fact that the expression of α5-GABAARs 
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is lower in these regions.33 
 
Conclusions and future directions 
This study provides evidence that antipsychotic-free patients with schizophrenia have lower GABA-A 
receptors in the hippocampus, predominantly of the alpha-5 subtype, that is not seen in antipsychotic 
treated patients. These findings are consistent with the hypothesis that GABA hypofunction underlies 
the pathophysiology of the disorder, and highlights the potential of GABA-ergic modulators as 
therapeutic targets for schizophrenia. 
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